150 related articles for article (PubMed ID: 25562819)
1. Serum CD166: a novel hepatocellular carcinoma tumor marker.
Ma L; Lin J; Qiao Y; Weng W; Liu W; Wang J; Sun F
Clin Chim Acta; 2015 Feb; 441():156-62. PubMed ID: 25562819
[TBL] [Abstract][Full Text] [Related]
2. Neuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma.
Lin J; Zhang Y; Wu J; Li L; Chen N; Ni P; Song L; Liu X
Clin Chim Acta; 2018 Oct; 485():158-165. PubMed ID: 29966621
[TBL] [Abstract][Full Text] [Related]
3. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases.
Tian L; Wang Y; Xu D; Gui J; Jia X; Tong H; Wen X; Dong Z; Tian Y
Int J Cancer; 2011 Oct; 129(8):1923-31. PubMed ID: 21140449
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
5. CD166 positively regulates MCAM via inhibition to ubiquitin E3 ligases Smurf1 and βTrCP through PI3K/AKT and c-Raf/MEK/ERK signaling in Bel-7402 hepatocellular carcinoma cells.
Tang X; Chen X; Xu Y; Qiao Y; Zhang X; Wang Y; Guan Y; Sun F; Wang J
Cell Signal; 2015 Sep; 27(9):1694-702. PubMed ID: 26004137
[TBL] [Abstract][Full Text] [Related]
6. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
7. [Serum and tissue expressions of galectin-3 in hepatocellular carcinoma and the clinical significances].
Fang QQ; Ni RZ; Xiao MB; Jiang F; Lu CH
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):527-31. PubMed ID: 22152245
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
10. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
11. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
12. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
14. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
15. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
Shimizu Y; Minemura M; Tsukishiro T; Kashii Y; Miyamoto M; Nishimori H; Higuchi K; Watanabe A
Hepatology; 1995 Aug; 22(2):525-31. PubMed ID: 7543436
[TBL] [Abstract][Full Text] [Related]
16. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
17. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.
Qiao SS; Cui ZQ; Gong L; Han H; Chen PC; Guo LM; Yu X; Wei YH; Ha SA; Kim JW; Jin ZT; Li S; Peng JR; Leng XS
Hepatogastroenterology; 2011; 58(110-111):1718-24. PubMed ID: 21940340
[TBL] [Abstract][Full Text] [Related]
19. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
20. DR-70 immunoassay for the surveillance of hepatocellular carcinoma.
Lin SZ; Chen CC; Lee KC; Tseng CW; Lin HY; Chen YC; Lin HC
J Gastroenterol Hepatol; 2012 Mar; 27(3):547-52. PubMed ID: 21883455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
